ClinicalTrials.gg
CompletedNCT04860297Updated Jun 18, 2024Results posted

A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants

A Phase 3 interventional study of mRNA-1273 in SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 15 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-18.

Primary conditionCOVID-19Registry: Coronavirus InfectionsReclassifiedWhy we changed it
Registry
Coronavirus Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The study's title name COVID-19, a narrower term within Coronavirus Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
234
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 — 2 open to participants now, 5 under way, 1 of them phase 3. 2019-nCoV Vaccine mRNA-1273 · COVID-19.

Enrollment
25th of 36
234 · median 499
Started
2021
with 20 others
Phase 3
10 of 36
none open now
Registered
14th of 36
by date
Lead sponsor
11 of 36
ModernaTX, Inc.

Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, this one is the 25th largest by enrollment, is one of 21 that started in 2021, is one of 10 in phase 3, and was the 14th registered.

COVID-19

7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About 2019-nCoV Vaccine mRNA-1273

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, or all of them as a file.
02

Study summary

This is an open-label study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1273 Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) vaccine in adults with a kidney or liver solid organ transplant (SOT) and in healthy adult participants. The primary goal of the study is to evaluate the safety of mRNA-1273 and the serum antibody (Ab) responses obtained 28 days after the last dose of mRNA-1273.

03

Conditions studied

  • SARS-CoV-2

Browse trials for

Keywords

  • mRNA-1273
  • mRNA-1273 vaccine
  • SARS-CoV-2
  • SARS-CoV-2 Vaccine
  • Coronavirus
  • Virus Diseases
  • Messenger RNA
  • COVID-19
  • COVID-19 Vaccine
  • Moderna
04

In context

COVID-19 Reclassified

7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.

This study's enrollment of 234 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.

Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Transplant Recipients

Key Inclusion Criteria for Part A:

  • Is either a kidney or a liver transplant recipient who is at least 90 days after transplantation at the time of consent, and is either unvaccinated or previously vaccinated with 2 doses of Moderna COVID-19 vaccine who is at least 1 month after the second dose at the time of consent. Participants who received the 2 doses of Moderna COVID-19 vaccine before transplant are not eligible.
  • Understands, agrees, and is able to comply with the study procedures and provides written .
  • Received chronic therapy for the prevention of allograft rejection for a minimum of 90 days before signing consent, including but not limited to: (such as, prednisolone), immunophilin binding agents (such as, calcineurin inhibitors, mTOR inhibitors), or inhibitors of de novo nucleotide synthesis (such as, mycophenolic acid, mizoribine, leflunomide, azathioprine).
  • For female participants of : negative pregnancy test, adequate or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection, agreement to continue adequate contraception or abstinence through 3 months following the second dose (Day 29) for those receiving 2-dose regimen and, through 3 months following the third dose (Day 85) for those receiving 3-dose regimen, and through 3 months following the third dose (Day 1) for those previously vaccinated SOT participants, and not currently breastfeeding.
  • Is medically stable, according to investigator's judgment, during the 3 months before signing consent.

Key Exclusion Criteria for Part A:

  • Has prior or planned administration of a coronavirus vaccine (for example, SARS-CoV-2 [for unvaccinated participants only], SARS-CoV, or MERS [Middle East Respiratory Syndrome] -CoV vaccine).
  • Has current treatment with agents for either prophylaxis against COVID-19 (for unvaccinated participants only) or treatment of COVID-19 (such as, anti-SARS-CoV-2 monoclonal antibodies).
  • A history of more than one solid organ transplanted (such as, kidney and pancreas). A history of previous kidney or liver transplant is acceptable.
  • Has received therapies that have depleting properties on T cells, B cells, and plasma cells (examples of depletional therapies include, but are not limited to, antithymocyte globulin [ATG], monoclonal antibodies, and proteosome inhibitors) within the last 3 months prior to enrollment.
  • A history of -proven T-cell- or Ab-mediated rejection within 3 months of informed consent, or suspected active or chronic rejection according to the investigator's judgment.
  • Has a known close contact with anyone with laboratory confirmed SARS-CoV-2 infection within 2 weeks to vaccine administration or known history of SARS-CoV-2 infection or positive SARS-CoV-2 test.
  • Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation or that could interfere with safety assessments or interpretation of results according to the investigator's judgment.
  • Has a history of donor-specific Ab.
  • Has a history of complications of immunosuppression
  • Suspected clinically relevant active hepatitis, including viral hepatitis, according to the investigator's judgment
  • Known (HIV) infection
  • Has a history of a diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety.
  • Received any non-study vaccine within 28 days before or after any dose of vaccine (except for seasonal influenza vaccine, which is not permitted within 14 days before or after any dose of vaccine)
  • Received intravenous blood products (red blood cells, , immunoglobulins) within 3 months prior to Day 1.
  • Participated in an interventional clinical study within 28 days prior to Day 0 or plans to donate blood products while participating in this study.

Healthy Participants

Key Inclusion Criteria for Part A:

  • In good general health without current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition, according to investigator assessment, at the time of consent, and has not been vaccinated with any COVID-19 vaccine at the time of consent.
  • Understands, agrees, and is able to comply with the study procedures and provides written informed consent.
  • For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection (Day 1), agreement to continue adequate contraception or abstinence through 3 months following the second injection (Day 29), and not currently breastfeeding.
  • Is medically stable, according to investigator's judgment, during the 3 months before signing consent.

Key Exclusion Criteria for Part A:

  • Has a known close contact with anyone with laboratory confirmed SARS-CoV-2 infection or COVID-19 within 2 weeks prior to vaccine administration or known history of SARS-CoV-2 infection or positive SARS-CoV-2 test.
  • Has prior or planned administration of a coronavirus vaccine (for example, SARS-CoV-2, SARS-CoV, or MERS-CoV vaccine).
  • Has current treatment with investigational agents for either prophylaxis against COVID-19 or treatment of COVID-19 (for example, anti-SARS-CoV-2 monoclonal antibodies).
  • Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation or that could interfere with safety assessments or interpretation of results according to the investigator's judgment.
  • Has a history of a diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety.
  • Received any non-study vaccine within 28 days before or after any dose of vaccine (except for seasonal influenza vaccine, which is not permitted within 14 days before or after any dose of vaccine)
  • Received intravenous blood products (red blood cells, platelets, immunoglobulins) within 3 months prior to Day 1.
  • Received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids ≥20 mg/day of prednisone equivalent).
  • Participated in an interventional clinical study within 28 days prior to Day 0 or plans to donate blood products while participating in this study.

Inclusion Criteria for Part B:

  • Participants must have been previously enrolled in this study (mRNA-1273-P304), are actively participating in Part A, and at least 4 months from the last dose; or participant is either a kidney or a liver SOT recipient who is at least 90 days after transplantation at the time of consent and who completed primary vaccination series (3 doses for mRNA COVID-19 vaccine; 2 doses for non-mRNA COVID-19 vaccine or at least 1 dose of non-mRNA combined with 1 dose of mRNA COVID-19 vaccine) under the EUA who are at least 4 months from the last dose. All primary COVID-19 vaccination series must be completed after transplant.
  • Female participants of childbearing potential may be enrolled in the study if the participant has a negative pregnancy test on the day of the first injection (booster dose Day 1).

Exclusion Criteria for Part B:

  • Exclusion Criteria in Part A will apply except:

    1. prior or planned administration of a coronavirus vaccine and current treatment with investigational agents for either prophylaxis against COVID-19.
    2. known close contact with anyone with laboratory-confirmed SARS-CoV-2 infection or COVID-19 within 2 weeks prior to vaccine administration or any known history of SARS-CoV-2 infection or positive SARSCoV-2 test will apply only to new SOT participants who will be enrolled in Part B.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

06

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
234 participants (actual)

Study arms

  • Experimental
    mRNA-1273

    Part A: All participants (healthy participants and SOT participants) who were unvaccinated prior to enrollment will receive 2 intramuscular (IM) injections of 100 microgram (µg) mRNA-1273 on Day 1 and Day 29. All SOT participants who were unvaccinated prior to enrollment will be offered the opportunity to receive a third primary dose of mRNA-1273 at Day 85 as per the emergency use authorization (EUA) Fact Sheet available at the time of protocol finalization. SOT participants who were previously vaccinated with 2 doses of Moderna COVID-19 vaccine under the EUA prior to enrollment will receive Dose 3 on Day 1. Part B: All eligible participants from Part A will be offered to receive a 100 µg booster dose of mRNA-1273 who are at least 4 months from the last dose. SOT recipients who completed primary COVID-19 vaccination series under EUA (outside of the mRNA-1273-P304 study) will receive a 100 µg booster dose on booster dose Day 1.

    Biological: mRNA-1273

Interventions

  • BiologicalmRNA-1273

    Sterile liquid for injection

07

What researchers measure

Primary outcomes

  1. Parts A and B: Number of SOT Participants With Unsolicited Adverse Events (AEs)

    An unsolicited AE was any AE reported by the participant that was not specified as a solicited adverse reaction (AR) or was specified as a solicited AR but started outside the protocol-defined period for reporting solicited ARs (that is, for the 7 days after each dose of vaccine). A summary of serious adverse events (SAEs) and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: Up to 28 days post-vaccination

  2. Parts A and B: Number of Healthy Participants With Unsolicited AEs

    An unsolicited AE was any AE reported by the participant that was not specified as a solicited AR or was specified as a solicited AR but started outside the protocol-defined period for reporting solicited ARs (that is, for the 7 days after each dose of vaccine). A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: Up to 28 days post-vaccination

  3. Parts A and B: Number of SOT Participants With Medically-Attended Adverse Events (MAAEs)

    An MAAE was an AE that led to an unscheduled visit to an healthcare practitioner (HCP). This included visits to a study site for unscheduled assessments (for example, abnormal laboratory test results follow-up, COVID-19) and visits to HCPs external to the study site (for example, urgent care, primary care physician). MAAEs were also required by protocol for routine surveillance of participants with symptoms for COVID-19 infection (fever, shortness of breath, cough, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea). All confirmed symptomatic COVID-19 cases were recorded as MAAEs. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: Throughout the study period (up to Day 450)

  4. Parts A and B: Number of Healthy Participants With MAAEs

    An MAAE was an AE that led to an unscheduled visit to an HCP. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory test results follow-up, COVID-19) and visits to HCPs external to the study site (for example, urgent care, primary care physician). MAAEs were also required by protocol for routine surveillance of participants with symptoms for COVID-19 infection (fever, shortness of breath, cough, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea). All confirmed symptomatic COVID-19 cases were recorded as MAAEs. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: Throughout the study period (up to Day 394)

  5. Parts A and B: Number of SOT Participants With Serious Adverse Events (SAEs)

    An AE (including an AR) was considered an SAE if, in the view of either the investigator or Sponsor, it results in any of the following outcomes: death, was life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly or birth defect, or medically important event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: Throughout the study period (up to Day 450)

  6. Parts A and B: Number of Healthy Participants With SAEs

    An AE (including an AR) was considered an SAE if, in the view of either the investigator or Sponsor, it results in any of the following outcomes: death, was life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly or birth defect, or medically important event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: Throughout the study period (up to Day 394)

  7. Parts A and B: Number of SOT Participants With Adverse Event of Special Interests (AESIs), Including Myocarditis/Pericarditis

    An AESI was an AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: Throughout the study period (up to Day 450)

  8. Parts A and B: Number of Healthy Participants With AESIs, Including Myocarditis/Pericarditis

    An AESI was an AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: Throughout the study period (up to Day 394)

  9. Parts A and B: Number of SOT Participants With AEs Leading to Discontinuation From Dosing and/or Study Participation (Withdrawal)

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug-related. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: Throughout the study period (up to Day 450)

  10. Parts A and B: Number of Healthy Participants With AEs Leading to Discontinuation From Dosing and/or Study Participation (Withdrawal)

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug-related. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: Throughout the study period (up to Day 394)

  11. Parts A and B: Number of SOT Participants With Adjudicated Biopsy-Proven Organ Rejection

    A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: Throughout the study period (up to Day 450)

  12. Parts A and B: Number of Healthy Participants With Biopsy-Proven Organ Rejection

    A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: Throughout the study period (up to Day 394)

  13. Parts A and B: Number of SOT Participants With Solicited Local and Systemic Adverse Reactions (ARs)

    Solicited ARs, including local and systemic ARs were collected in the eDiary. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. All solicited ARs (local and systemic) considered causally related to injection. ARs were graded 0-4 as reviewed and confirmed by Investigator; lower score indicates lower severity and a higher score indicates greater severity. Note, not all solicited ARs were considered AEs. The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: 7 days post-vaccination

  14. Parts A and B: Number of Healthy Participants With Solicited Local and Systemic ARs

    Solicited ARs, including local and systemic ARs were collected in the eDiary. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. All solicited ARs (local and systemic) considered causally related to injection. ARs were graded 0-4 as reviewed and confirmed by Investigator; lower score indicates lower severity and a higher score indicates greater severity. Note, not all solicited ARs were considered AEs. The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: 7 days post-vaccination

  15. Part A: Geometric Mean Concentration (GMC) of Serum SARS-CoV-2-Specific Neutralizing Antibody (nAb) After the Second Dose in Unvaccinated Participants

    The GMC of VAC62 antibodies, as measured by pseudovirus neutralization assay (PsVNA) specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values that were greater than the upper limit of quantification (ULOQ) were converted to the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 arbitrary units (AU)/milliliter (mL). The 95% confidence intervals (CIs) were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons.

    Time frame: Day 57 (for unvaccinated participants)

  16. Part A: GMC of SARS-CoV-2-Specific nAb 28 Days After Dose 3

    The GMC of VAC62 antibodies, as measured by PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation.

    Time frame: 28 days after Dose 3

  17. Part B: GMC of SARS-CoV-2-Specific nAb 28 Days After the BD in SOT Participants Who Received the Moderna Primary Series and Non-Moderna Primary Series

    The GMC of VAC62 antibodies, as measured by PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation.

    Time frame: 28 days after BD injection (BD-Day 29)

Secondary outcomes

  1. Part A: GMC of SARS-CoV-2-Specific nAb for Unvaccinated Participants Receiving the 2-Dose Regimen

    The GMC of VAC62 antibodies, as measured by pseudovirus neutralization assay PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons. 95% CI cannot be calculated with an 'N' less than 2.

    Time frame: Days 1, 28 days after Dose 1, 28 days after Dose 2, 6 months after Dose 2, and 1 year after Dose 2

  2. Part A: GMC of SARS-CoV-2-Specific nAb for Unvaccinated and Previously Vaccinated Participants Receiving the 3-Dose Regimen

    The GMC of VAC62 antibodies, as measured by pseudovirus neutralization assay PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons.

    Time frame: 28 days after Dose 3, 6 months after Dose 3, and 1 year after Dose 3

  3. Part A: GMFR of nAb for Unvaccinated Participants Receiving the 2-Dose Regimen Relative to Day 1

    The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. The GMFR of VAC62 antibodies, as measured by PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons. 95% CI cannot be calculated with an 'N' less than 2.

    Time frame: 28 days after Dose 1, 28 days after Dose 2, 6 months after Dose 2, and 1 year after Dose 2

  4. Part A: GMFR of nAb for Unvaccinated and Previously Vaccinated Participants Receiving the 3-Dose Regimen Relative to Day 1

    The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. The GMFR of VAC62 antibodies, as measured by PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons.

    Time frame: 28 days after Dose 3, 6 months after Dose 3, 1 year after Dose 3

  5. Part A: Geometric Mean (GM) Value of Anti-SARS-CoV-2 S-specific Binding Antibody (bAb) for Unvaccinated Participants Receiving the 2-Dose Regimen

    The GM level of VAC123 spike antibodies, as measured by MesoScale Discovery (MSD) electrochemiluminescence (ECL) multiplex assay specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 69 and ULOQ was 14400000 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons. 95% CI cannot be calculated with an 'N' less than 2.

    Time frame: Days 1, 28 days after Dose 1, 28 days after Dose 2, 6 months after Dose 2, and 1 year after Dose 2

  6. Part A: GM Value of Anti-SARS-CoV-2 S-specific bAb for Unvaccinated and Previously Vaccinated Participants Receiving the 3-Dose Regimen

    The GM level of VAC123 spike antibodies, as measured by MSD ECL multiplex assay specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 69 and ULOQ was 14400000 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons.

    Time frame: 28 days after Dose 3, 6 months after Dose 3, and 1 year after Dose 3

  7. Part A: Geometric Mean Fold-Rise (GMFR) of bAb for Unvaccinated Participants Receiving the 2-Dose Regimen Relative to Day 1

    The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. The GMFR of VAC123 spike antibodies, as measured by MSD ECL multiplex assay specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 69 and ULOQ was 14400000 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons. 95% CI cannot be calculated with an 'N' less than 2.

    Time frame: 28 days after Dose 1, 28 days after Dose 2, 6 months after Dose 2, and 1 year after Dose 2

  8. Part A: GMFR of bAb for Unvaccinated and Previously Vaccinated Participants Receiving the 3-Dose Regimen Relative to Day 1

    The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. The GMFR of VAC123 spike antibodies, as measured by MSD ECL multiplex assay specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 69 and ULOQ was 14400000 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons.

    Time frame: 28 days after Dose 3, 6 months after Dose 3, 1 year after Dose 3

  9. Part A: Number of SOT Participants With Asymptomatic SARS-CoV-2 Infection

    Asymptomatic SARS-CoV-2 infection was identified by absence of COVID-19 symptoms and infections as detected by reverse transcriptase polymerase chain reaction (RT-PCR) central or local test or serology test as binding antibody (bAb) level against SARS-CoV-2 nucleocapsid protein negative (as measured by Roche Elecsys) at Day 1 that became positive (as measured by Roche Elecsys) post-baseline or positive RT-PCR (CLIA-certified central or local) laboratory post-baseline at scheduled or unscheduled/illness visits. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: 14 days after second and third injection

  10. Part A: Number of Healthy Participants With Asymptomatic SARS-CoV-2 Infection

    Asymptomatic SARS-CoV-2 infection was identified by absence of COVID-19 symptoms and infections as detected by reverse transcriptase polymerase chain reaction (RT-PCR1) central or local test or serology test as bAb level against SARS-CoV-2 nucleocapsid protein negative (as measured by Roche Elecsys) at Day 1 that became positive (as measured by Roche Elecsys) post-baseline or positive RT-PCR (CLIA-certified central or local) laboratory post-baseline at scheduled or unscheduled/illness visits. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: 14 days after second and third injection

  11. Part A: Number of SOT Participants With the Occurrence of COVID-19

    COVID-19 case was identified as a positive post-baseline RT-PCR (CLIA-certified central or local) laboratory for SARS-CoV-2, together with at least 2 systemic symptoms: fever (≥ 38 degree celsius \[°C\]/≥ 100.4 degree fahrenheit \[°F\]), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s), or at least 1 of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: 14 days after second and third injection

  12. Part A: Number of Healthy Participants With the Occurrence of COVID-19

    COVID-19 case was identified as a positive post-baseline RT-PCR (CLIA-certified central or local) laboratory for SARS-CoV-2, together with at least 2 systemic symptoms: fever (≥ 38°C/≥ 100.4°F), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s), or at least 1 of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: 14 days after second and third injection

  13. Part A: Number of SOT Participants With the Occurrence of Severe COVID-19

    Severe COVID-19 case was identified as a COVID-19 case (RT-PCR \[CLIA-certified central or local\] laboratory) for SARS-CoV-2, together with any of the following: respiratory rate ≥30 per minute, heart rate ≥125 beats per minute, oxygen saturation(SpO2) ≤93% on room air at sea level, or partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FIO2) \<300 millimeters of mercury (mmHg); or respiratory failure or acute respiratory distress syndrome (ARDS), defined as needing high-flow oxygen, noninvasive or mechanical ventilation, or extracorporeal membrane oxygenation) or evidence of shock (systolic blood pressure \<90 mm Hg, diastolic BP \<60 mm Hg, or requiring vasopressors); or significant acute renal, hepatic, or neurologic dysfunction; OR admission to an intensive care unit or death. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: 14 days after second and third injection

  14. Part A: Number of Healthy Participants With the Occurrence of Severe COVID-19

    Severe COVID-19 case was identified as a COVID-19 case (RT-PCR \[CLIA-certified central or local\] laboratory) for SARS-CoV-2, together with any of the following: respiratory rate ≥30 per minute, heart rate ≥125 beats per minute, oxygen saturation(SpO2) ≤93% on room air at sea level, or partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FIO2) \<300 millimeters of mercury (mmHg); or respiratory failure or acute respiratory distress syndrome (ARDS), defined as needing high-flow oxygen, noninvasive or mechanical ventilation, or extracorporeal membrane oxygenation) or evidence of shock (systolic blood pressure \<90 mm Hg, diastolic BP \<60 mm Hg, or requiring vasopressors); or significant acute renal, hepatic, or neurologic dysfunction; OR admission to an intensive care unit or death. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: 14 days after second and third injection

  15. Parts A and B: Number of SOT Participants Who Changed Immunosuppressant Therapy

    A summary of serious adverse events (SAEs) and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: Throughout the study period (up to Day 450)

08

Results

Posted Jun 18, 2024
Limitations and caveats
Healthy participants cohort was included as a control group in the evaluation of humoral and cell-mediated immune response only; no comparisons of safety data with the healthy participants were made.

Participant flow

A total of 214 solid organ transplant (SOT) participants (137 SOT kidney and 77 SOT liver participants) and 20 healthy participants were enrolled for the study.

Part A (Primary Series)
Participant flow — Part A (Primary Series)
MilestonePart A (Primary Series): Cohort A1 - SOT ParticipantsPart A (Primary Series): Cohort A2 - SOT ParticipantsPart A (Primary Series): Cohort A3 - SOT ParticipantsPart A (Primary Series): Cohort A5 - Healthy ParticipantsPart B (Booster Dose): Cohort B2 - SOT ParticipantsPart B (Booster Dose): Cohort B3 - SOT ParticipantsPart B (Booster Dose): Cohort B4 - SOT ParticipantsPart B (Booster Dose): Cohort B5 - Healthy Participants
Started35871200000
Received first study injection3580200000
Received second study injection358000000
Received third study injection0577100000
Completed25771170000
Not completed11030000
Withdrew: Withdrawal by subject01010000
Withdrew: Lost to follow-up10020000
Part B (Booster Dose)
Participant flow — Part B (Booster Dose)
MilestonePart A (Primary Series): Cohort A1 - SOT ParticipantsPart A (Primary Series): Cohort A2 - SOT ParticipantsPart A (Primary Series): Cohort A3 - SOT ParticipantsPart A (Primary Series): Cohort A5 - Healthy ParticipantsPart B (Booster Dose): Cohort B2 - SOT ParticipantsPart B (Booster Dose): Cohort B3 - SOT ParticipantsPart B (Booster Dose): Cohort B4 - SOT ParticipantsPart B (Booster Dose): Cohort B5 - Healthy Participants
Started000033448210
Received booster injection000033448110
Completed00002934787
Not completed000041043
Withdrew: Protocol deviation00000010
Withdrew: Other than specified00000110
Withdrew: Withdrawal by subject00000201
Withdrew: Death00001210
Withdrew: Lost to follow-up00003512

Outcome measures

PrimaryParts A and B: Number of SOT Participants With Unsolicited Adverse Events (AEs)

An unsolicited AE was any AE reported by the participant that was not specified as a solicited adverse reaction (AR) or was specified as a solicited AR but started outside the protocol-defined period for reporting solicited ARs (that is, for the 7 days after each dose of vaccine). A summary of serious adverse events (SAEs) and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
Up to 28 days post-vaccination
Reported as:
Count of participants · Participants
Parts A and B: Number of SOT Participants With Unsolicited Adverse Events (AEs)
ParticipantsSOT Kidney ParticipantsSOT Liver ParticipantsSOT Total
Parts A and B: Number of SOT Participants With Unsolicited Adverse Events (AEs)484189
PrimaryParts A and B: Number of Healthy Participants With Unsolicited AEs

An unsolicited AE was any AE reported by the participant that was not specified as a solicited AR or was specified as a solicited AR but started outside the protocol-defined period for reporting solicited ARs (that is, for the 7 days after each dose of vaccine). A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
Up to 28 days post-vaccination
Reported as:
Count of participants · Participants
Parts A and B: Number of Healthy Participants With Unsolicited AEs
ParticipantsHealthy Participants
Parts A and B: Number of Healthy Participants With Unsolicited AEs12
PrimaryParts A and B: Number of SOT Participants With Medically-Attended Adverse Events (MAAEs)

An MAAE was an AE that led to an unscheduled visit to an healthcare practitioner (HCP). This included visits to a study site for unscheduled assessments (for example, abnormal laboratory test results follow-up, COVID-19) and visits to HCPs external to the study site (for example, urgent care, primary care physician). MAAEs were also required by protocol for routine surveillance of participants with symptoms for COVID-19 infection (fever, shortness of breath, cough, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea). All confirmed symptomatic COVID-19 cases were recorded as MAAEs. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
Throughout the study period (up to Day 450)
Reported as:
Count of participants · Participants
Parts A and B: Number of SOT Participants With Medically-Attended Adverse Events (MAAEs)
ParticipantsSOT Kidney ParticipantsSOT Liver ParticipantsSOT Total
Parts A and B: Number of SOT Participants With Medically-Attended Adverse Events (MAAEs)8656142
PrimaryParts A and B: Number of Healthy Participants With MAAEs

An MAAE was an AE that led to an unscheduled visit to an HCP. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory test results follow-up, COVID-19) and visits to HCPs external to the study site (for example, urgent care, primary care physician). MAAEs were also required by protocol for routine surveillance of participants with symptoms for COVID-19 infection (fever, shortness of breath, cough, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea). All confirmed symptomatic COVID-19 cases were recorded as MAAEs. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
Throughout the study period (up to Day 394)
Reported as:
Count of participants · Participants
Parts A and B: Number of Healthy Participants With MAAEs
ParticipantsHealthy Participants
Parts A and B: Number of Healthy Participants With MAAEs14
PrimaryParts A and B: Number of SOT Participants With Serious Adverse Events (SAEs)

An AE (including an AR) was considered an SAE if, in the view of either the investigator or Sponsor, it results in any of the following outcomes: death, was life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly or birth defect, or medically important event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
Throughout the study period (up to Day 450)
Reported as:
Count of participants · Participants
Parts A and B: Number of SOT Participants With Serious Adverse Events (SAEs)
ParticipantsSOT Kidney ParticipantsSOT Liver ParticipantsSOT Total
Parts A and B: Number of SOT Participants With Serious Adverse Events (SAEs)291948
PrimaryParts A and B: Number of Healthy Participants With SAEs

An AE (including an AR) was considered an SAE if, in the view of either the investigator or Sponsor, it results in any of the following outcomes: death, was life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly or birth defect, or medically important event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
Throughout the study period (up to Day 394)
Reported as:
Count of participants · Participants
Parts A and B: Number of Healthy Participants With SAEs
ParticipantsHealthy Participants
Parts A and B: Number of Healthy Participants With SAEs1
PrimaryParts A and B: Number of SOT Participants With Adverse Event of Special Interests (AESIs), Including Myocarditis/Pericarditis

An AESI was an AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
Throughout the study period (up to Day 450)
Reported as:
Count of participants · Participants
Parts A and B: Number of SOT Participants With Adverse Event of Special Interests (AESIs), Including Myocarditis/Pericarditis
ParticipantsSOT Kidney ParticipantsSOT Liver ParticipantsSOT Total
Parts A and B: Number of SOT Participants With Adverse Event of Special Interests (AESIs), Including Myocarditis/Pericarditis151328
PrimaryParts A and B: Number of Healthy Participants With AESIs, Including Myocarditis/Pericarditis

An AESI was an AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
Throughout the study period (up to Day 394)
Reported as:
Count of participants · Participants
Parts A and B: Number of Healthy Participants With AESIs, Including Myocarditis/Pericarditis
ParticipantsHealthy Participants
Parts A and B: Number of Healthy Participants With AESIs, Including Myocarditis/Pericarditis1
PrimaryParts A and B: Number of SOT Participants With AEs Leading to Discontinuation From Dosing and/or Study Participation (Withdrawal)

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug-related. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
Throughout the study period (up to Day 450)
Reported as:
Count of participants · Participants
Parts A and B: Number of SOT Participants With AEs Leading to Discontinuation From Dosing and/or Study Participation (Withdrawal)
ParticipantsSOT Kidney ParticipantsSOT Liver ParticipantsSOT Total
Parts A and B: Number of SOT Participants With AEs Leading to Discontinuation From Dosing and/or Study Participation (Withdrawal)404
PrimaryParts A and B: Number of Healthy Participants With AEs Leading to Discontinuation From Dosing and/or Study Participation (Withdrawal)

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug-related. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
Throughout the study period (up to Day 394)
Reported as:
Count of participants · Participants
Parts A and B: Number of Healthy Participants With AEs Leading to Discontinuation From Dosing and/or Study Participation (Withdrawal)
ParticipantsHealthy Participants
Parts A and B: Number of Healthy Participants With AEs Leading to Discontinuation From Dosing and/or Study Participation (Withdrawal)0
PrimaryParts A and B: Number of SOT Participants With Adjudicated Biopsy-Proven Organ Rejection

A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
Throughout the study period (up to Day 450)
Reported as:
Count of participants · Participants
Parts A and B: Number of SOT Participants With Adjudicated Biopsy-Proven Organ Rejection
ParticipantsSOT Kidney ParticipantsSOT Liver ParticipantsSOT Total
Parts A and B: Number of SOT Participants With Adjudicated Biopsy-Proven Organ Rejection123
PrimaryParts A and B: Number of Healthy Participants With Biopsy-Proven Organ Rejection

A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
Throughout the study period (up to Day 394)
Reported as:
Count of participants · Participants
Parts A and B: Number of Healthy Participants With Biopsy-Proven Organ Rejection
ParticipantsHealthy Participants
Parts A and B: Number of Healthy Participants With Biopsy-Proven Organ Rejection0
PrimaryParts A and B: Number of SOT Participants With Solicited Local and Systemic Adverse Reactions (ARs)

Solicited ARs, including local and systemic ARs were collected in the eDiary. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. All solicited ARs (local and systemic) considered causally related to injection. ARs were graded 0-4 as reviewed and confirmed by Investigator; lower score indicates lower severity and a higher score indicates greater severity. Note, not all solicited ARs were considered AEs. The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
7 days post-vaccination
Reported as:
Count of participants · Participants
Parts A and B: Number of SOT Participants With Solicited Local and Systemic Adverse Reactions (ARs)
ParticipantsSOT Kidney ParticipantsSOT Liver ParticipantsSOT Total
Solicited Local ARs11665181
Solicited Systemic ARs10270172
PrimaryParts A and B: Number of Healthy Participants With Solicited Local and Systemic ARs

Solicited ARs, including local and systemic ARs were collected in the eDiary. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. All solicited ARs (local and systemic) considered causally related to injection. ARs were graded 0-4 as reviewed and confirmed by Investigator; lower score indicates lower severity and a higher score indicates greater severity. Note, not all solicited ARs were considered AEs. The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
7 days post-vaccination
Reported as:
Count of participants · Participants
Parts A and B: Number of Healthy Participants With Solicited Local and Systemic ARs
ParticipantsHealthy Participants
Solicited Local ARs16
Solicited Systemic ARs19
PrimaryPart A: Geometric Mean Concentration (GMC) of Serum SARS-CoV-2-Specific Neutralizing Antibody (nAb) After the Second Dose in Unvaccinated Participants

The GMC of VAC62 antibodies, as measured by pseudovirus neutralization assay (PsVNA) specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values that were greater than the upper limit of quantification (ULOQ) were converted to the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 arbitrary units (AU)/milliliter (mL). The 95% confidence intervals (CIs) were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons.

Time frame:
Day 57 (for unvaccinated participants)
Reported as:
Geometric mean · AU/mL
Part A: Geometric Mean Concentration (GMC) of Serum SARS-CoV-2-Specific Neutralizing Antibody (nAb) After the Second Dose in Unvaccinated Participants
AU/mLPart A: SOT Kidney (Unvaccinated Participants)Part A: SOT Liver (Unvaccinated Participants)Healthy Participants
Part A: Geometric Mean Concentration (GMC) of Serum SARS-CoV-2-Specific Neutralizing Antibody (nAb) After the Second Dose in Unvaccinated Participants54.2 (23.4 to 125.5)187.9 (67.6 to 522.6)1658.4 (951.1 to 2891.6)
PrimaryPart A: GMC of SARS-CoV-2-Specific nAb 28 Days After Dose 3

The GMC of VAC62 antibodies, as measured by PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation.

Time frame:
28 days after Dose 3
Reported as:
Geometric mean · AU/mL
Part A: GMC of SARS-CoV-2-Specific nAb 28 Days After Dose 3
AU/mLSOT Kidney ParticipantsSOT Liver ParticipantsSOT Total
Part A: GMC of SARS-CoV-2-Specific nAb 28 Days After Dose 3353.5 (171.2 to 729.7)1340.2 (617.4 to 2909.1)538.4 (307.2 to 943.7)
PrimaryPart B: GMC of SARS-CoV-2-Specific nAb 28 Days After the BD in SOT Participants Who Received the Moderna Primary Series and Non-Moderna Primary Series

The GMC of VAC62 antibodies, as measured by PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation.

Time frame:
28 days after BD injection (BD-Day 29)
Reported as:
Geometric mean · AU/mL
Part B: GMC of SARS-CoV-2-Specific nAb 28 Days After the BD in SOT Participants Who Received the Moderna Primary Series and Non-Moderna Primary Series
AU/mLPart B: SOT Kidney ParticipantsPart B: SOT Liver Participants
Part B: GMC of SARS-CoV-2-Specific nAb 28 Days After the BD in SOT Participants Who Received the Moderna Primary Series and Non-Moderna Primary Series430.7 (216.4 to 857.5)3946.0 (1944.5 to 8007.8)
SecondaryPart A: GMC of SARS-CoV-2-Specific nAb for Unvaccinated Participants Receiving the 2-Dose Regimen

The GMC of VAC62 antibodies, as measured by pseudovirus neutralization assay PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons. 95% CI cannot be calculated with an 'N' less than 2.

Time frame:
Days 1, 28 days after Dose 1, 28 days after Dose 2, 6 months after Dose 2, and 1 year after Dose 2
Reported as:
Geometric mean · AU/mL
Part A: GMC of SARS-CoV-2-Specific nAb for Unvaccinated Participants Receiving the 2-Dose Regimen
AU/mLPart A: SOT Kidney (Unvaccinated Participants)Part A: SOT Liver (Unvaccinated Participants)Healthy Participants
Day 113.9 (10.1 to 19.2)13.6 (8.0 to 23.2)11.2 (7.3 to 17.1)
28 days after Dose 118.6 (11.1 to 31.2)28.4 (15.2 to 53.1)58.2 (31.4 to 107.8)
28 days after Dose 254.2 (23.4 to 125.5)187.9 (67.6 to 522.6)1658.4 (951.1 to 2891.6)
6 months after Dose 2859.04134.0948.5 (322.7 to 2787.6)
1 year after Dose 2412.07285.01439.3 (100.8 to 20561.0)
SecondaryPart A: GMC of SARS-CoV-2-Specific nAb for Unvaccinated and Previously Vaccinated Participants Receiving the 3-Dose Regimen

The GMC of VAC62 antibodies, as measured by pseudovirus neutralization assay PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons.

Time frame:
28 days after Dose 3, 6 months after Dose 3, and 1 year after Dose 3
Reported as:
Geometric mean · AU/mL
Part A: GMC of SARS-CoV-2-Specific nAb for Unvaccinated and Previously Vaccinated Participants Receiving the 3-Dose Regimen
AU/mLSOT Kidney ParticipantsSOT Liver ParticipantsSOT Total
28 days after Dose 3353.5 (171.2 to 729.7)1340.2 (617.4 to 2909.1)538.4 (307.2 to 943.7)
6 months after Dose 3222.5 (72.7 to 681.4)867.2 (62.9 to 11960.3)292.1 (109.1 to 782.0)
1 year after Dose 3990.7 (198.6 to 4942.3)480.8 (NA to 4400000000000)899.7 (217.0 to 3729.4)
SecondaryPart A: GMFR of nAb for Unvaccinated Participants Receiving the 2-Dose Regimen Relative to Day 1

The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. The GMFR of VAC62 antibodies, as measured by PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons. 95% CI cannot be calculated with an 'N' less than 2.

Time frame:
28 days after Dose 1, 28 days after Dose 2, 6 months after Dose 2, and 1 year after Dose 2
Reported as:
Geometric mean · ratio
Part A: GMFR of nAb for Unvaccinated Participants Receiving the 2-Dose Regimen Relative to Day 1
ratioPart A: SOT Kidney (Unvaccinated Participants)Part A: SOT Liver (Unvaccinated Participants)Healthy Participants
28 days after Dose 11.3 (0.8 to 2.1)2.1 (0.9 to 5.0)5.2 (2.7 to 9.9)
28 days after Dose 23.7 (1.7 to 8.2)13.8 (3.7 to 51.9)148.4 (84.3 to 261.2)
6 months after Dose 2171.8826.896.4 (36.8 to 252.8)
1 year after Dose 282.41457.0145.1 (11.8 to 1778.7)
SecondaryPart A: GMFR of nAb for Unvaccinated and Previously Vaccinated Participants Receiving the 3-Dose Regimen Relative to Day 1

The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. The GMFR of VAC62 antibodies, as measured by PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons.

Time frame:
28 days after Dose 3, 6 months after Dose 3, 1 year after Dose 3
Reported as:
Geometric mean · ratio
Part A: GMFR of nAb for Unvaccinated and Previously Vaccinated Participants Receiving the 3-Dose Regimen Relative to Day 1
ratioSOT Kidney ParticipantsSOT Liver ParticipantsSOT Total
28 days after Dose 316.6 (6.6 to 41.7)56.8 (10.5 to 306.4)25.0 (11.2 to 55.9)
6 months after Dose 316.2 (4.2 to 62.7)65.8 (3.0 to 1429.9)25.8 (7.7 to 86.7)
1 year after Dose 3990.7 (198.6 to 4942.3)480.8 (NA to 4400000000000)899.7 (217.0 to 3729.4)
SecondaryPart A: Geometric Mean (GM) Value of Anti-SARS-CoV-2 S-specific Binding Antibody (bAb) for Unvaccinated Participants Receiving the 2-Dose Regimen

The GM level of VAC123 spike antibodies, as measured by MesoScale Discovery (MSD) electrochemiluminescence (ECL) multiplex assay specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 69 and ULOQ was 14400000 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons. 95% CI cannot be calculated with an 'N' less than 2.

Time frame:
Days 1, 28 days after Dose 1, 28 days after Dose 2, 6 months after Dose 2, and 1 year after Dose 2
Reported as:
Geometric mean · AU/mL
Part A: Geometric Mean (GM) Value of Anti-SARS-CoV-2 S-specific Binding Antibody (bAb) for Unvaccinated Participants Receiving the 2-Dose Regimen
AU/mLPart A: SOT Kidney (Unvaccinated Participants)Part A: SOT Liver (Unvaccinated Participants)Healthy Participants
Day 168.3 (39.9 to 116.9)59.1 (33.6 to 104.0)53.6 (34.4 to 83.4)
28 days after Dose 1346.4 (127.7 to 939.6)1213.9 (269.5 to 5467.4)23668.2 (13462.8 to 41609.8)
28 days after Dose 23190.1 (828.4 to 12284.7)20734.0 (3689.2 to 116527.2)272797.7 (188489.1 to 394816.2)
6 months after Dose 284460.0202997.097534.9 (47881.0 to 198681.0)
1 year after Dose 244828.0167863.0161241.8 (19006.2 to 1367917.7)
SecondaryPart A: GM Value of Anti-SARS-CoV-2 S-specific bAb for Unvaccinated and Previously Vaccinated Participants Receiving the 3-Dose Regimen

The GM level of VAC123 spike antibodies, as measured by MSD ECL multiplex assay specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 69 and ULOQ was 14400000 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons.

Time frame:
28 days after Dose 3, 6 months after Dose 3, and 1 year after Dose 3
Reported as:
Geometric mean · AU/mL
Part A: GM Value of Anti-SARS-CoV-2 S-specific bAb for Unvaccinated and Previously Vaccinated Participants Receiving the 3-Dose Regimen
AU/mLSOT Kidney ParticipantsSOT Liver ParticipantsSOT Total
28 days after Dose 326674.0 (10865.9 to 65480.5)167141.1 (69651.7 to 401083.3)47260.9 (23657.2 to 94415.1)
6 months after Dose 319289.6 (5878.6 to 63295.3)69076.5 (12838.6 to 371658.0)24895.7 (9274.4 to 66828.7)
1 year after Dose 366847.7 (16994.7 to 262942.2)42266.8 (NA to 664919284614.9)62884.2 (18998.9 to 208139.7)
SecondaryPart A: Geometric Mean Fold-Rise (GMFR) of bAb for Unvaccinated Participants Receiving the 2-Dose Regimen Relative to Day 1

The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. The GMFR of VAC123 spike antibodies, as measured by MSD ECL multiplex assay specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 69 and ULOQ was 14400000 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons. 95% CI cannot be calculated with an 'N' less than 2.

Time frame:
28 days after Dose 1, 28 days after Dose 2, 6 months after Dose 2, and 1 year after Dose 2
Reported as:
Geometric mean · ratio
Part A: Geometric Mean Fold-Rise (GMFR) of bAb for Unvaccinated Participants Receiving the 2-Dose Regimen Relative to Day 1
ratioPart A: SOT Kidney (Unvaccinated Participants)Part A: SOT Liver (Unvaccinated Participants)Healthy Participants
28 days after Dose 14.9 (1.8 to 13.4)20.5 (4.3 to 97.0)441.9 (244.5 to 798.5)
28 days after Dose 245.4 (10.7 to 191.8)399.0 (64.0 to 2488.0)5092.9 (3032.6 to 8553.1)
6 months after Dose 22448.15884.01710.0 (755.9 to 3868.5)
1 year after Dose 21299.44865.62567.2 (47.8 to 137952.8)
SecondaryPart A: GMFR of bAb for Unvaccinated and Previously Vaccinated Participants Receiving the 3-Dose Regimen Relative to Day 1

The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. The GMFR of VAC123 spike antibodies, as measured by MSD ECL multiplex assay specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 69 and ULOQ was 14400000 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons.

Time frame:
28 days after Dose 3, 6 months after Dose 3, 1 year after Dose 3
Reported as:
Geometric mean · ratio
Part A: GMFR of bAb for Unvaccinated and Previously Vaccinated Participants Receiving the 3-Dose Regimen Relative to Day 1
ratioSOT Kidney ParticipantsSOT Liver ParticipantsSOT Total
28 days after Dose 3275.5 (60.9 to 1246.2)1556.2 (219.1 to 11051.0)490.7 (151.8 to 1586.4)
6 months after Dose 3554.9 (161.0 to 1912.2)824.1 (124.9 to 5436.5)633.1 (251.7 to 1592.5)
1 year after Dose 3690.8 (71.7 to 6656.9)746.2 (NA to 6400000000000)701.5 (114.3 to 4305.5)
SecondaryPart A: Number of SOT Participants With Asymptomatic SARS-CoV-2 Infection

Asymptomatic SARS-CoV-2 infection was identified by absence of COVID-19 symptoms and infections as detected by reverse transcriptase polymerase chain reaction (RT-PCR) central or local test or serology test as binding antibody (bAb) level against SARS-CoV-2 nucleocapsid protein negative (as measured by Roche Elecsys) at Day 1 that became positive (as measured by Roche Elecsys) post-baseline or positive RT-PCR (CLIA-certified central or local) laboratory post-baseline at scheduled or unscheduled/illness visits. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
14 days after second and third injection
Reported as:
Count of participants · Participants
Part A: Number of SOT Participants With Asymptomatic SARS-CoV-2 Infection
ParticipantsPart A (Primary Series): Cohort A1 (SOT Kidney Participants)Part A (Primary Series): Cohort A1 (SOT Liver Participants)Part A (Primary Series): Cohort A2 and A3 (SOT Kidney Participants)Part A (Primary Series): Cohort A2 and A3 (SOT Liver Participants)
Part A: Number of SOT Participants With Asymptomatic SARS-CoV-2 Infection0184
SecondaryPart A: Number of Healthy Participants With Asymptomatic SARS-CoV-2 Infection

Asymptomatic SARS-CoV-2 infection was identified by absence of COVID-19 symptoms and infections as detected by reverse transcriptase polymerase chain reaction (RT-PCR1) central or local test or serology test as bAb level against SARS-CoV-2 nucleocapsid protein negative (as measured by Roche Elecsys) at Day 1 that became positive (as measured by Roche Elecsys) post-baseline or positive RT-PCR (CLIA-certified central or local) laboratory post-baseline at scheduled or unscheduled/illness visits. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
14 days after second and third injection
Reported as:
Count of participants · Participants
Part A: Number of Healthy Participants With Asymptomatic SARS-CoV-2 Infection
ParticipantsHealthy Participants
Part A: Number of Healthy Participants With Asymptomatic SARS-CoV-2 Infection4
SecondaryPart A: Number of SOT Participants With the Occurrence of COVID-19

COVID-19 case was identified as a positive post-baseline RT-PCR (CLIA-certified central or local) laboratory for SARS-CoV-2, together with at least 2 systemic symptoms: fever (≥ 38 degree celsius \[°C\]/≥ 100.4 degree fahrenheit \[°F\]), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s), or at least 1 of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
14 days after second and third injection
Reported as:
Count of participants · Participants
Part A: Number of SOT Participants With the Occurrence of COVID-19
ParticipantsPart A (Primary Series): Cohort A1 (SOT Kidney Participants)Part A (Primary Series): Cohort A1 (SOT Liver Participants)Part A (Primary Series): Cohort A2 and A3 (SOT Kidney Participants)Part A (Primary Series): Cohort A2 and A3 (SOT Liver Participants)
Part A: Number of SOT Participants With the Occurrence of COVID-1900127
SecondaryPart A: Number of Healthy Participants With the Occurrence of COVID-19

COVID-19 case was identified as a positive post-baseline RT-PCR (CLIA-certified central or local) laboratory for SARS-CoV-2, together with at least 2 systemic symptoms: fever (≥ 38°C/≥ 100.4°F), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s), or at least 1 of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
14 days after second and third injection
Reported as:
Count of participants · Participants
Part A: Number of Healthy Participants With the Occurrence of COVID-19
ParticipantsHealthy Participants
Part A: Number of Healthy Participants With the Occurrence of COVID-192
SecondaryPart A: Number of SOT Participants With the Occurrence of Severe COVID-19

Severe COVID-19 case was identified as a COVID-19 case (RT-PCR \[CLIA-certified central or local\] laboratory) for SARS-CoV-2, together with any of the following: respiratory rate ≥30 per minute, heart rate ≥125 beats per minute, oxygen saturation(SpO2) ≤93% on room air at sea level, or partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FIO2) \<300 millimeters of mercury (mmHg); or respiratory failure or acute respiratory distress syndrome (ARDS), defined as needing high-flow oxygen, noninvasive or mechanical ventilation, or extracorporeal membrane oxygenation) or evidence of shock (systolic blood pressure \<90 mm Hg, diastolic BP \<60 mm Hg, or requiring vasopressors); or significant acute renal, hepatic, or neurologic dysfunction; OR admission to an intensive care unit or death. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
14 days after second and third injection
Reported as:
Count of participants · Participants
Part A: Number of SOT Participants With the Occurrence of Severe COVID-19
ParticipantsPart A (Primary Series): Cohort A1 (SOT Kidney Participants)Part A (Primary Series): Cohort A1 (SOT Liver Participants)Part A (Primary Series): Cohort A2 and A3 (SOT Kidney Participants)Part A (Primary Series): Cohort A2 and A3 (SOT Liver Participants)
Part A: Number of SOT Participants With the Occurrence of Severe COVID-190012
SecondaryPart A: Number of Healthy Participants With the Occurrence of Severe COVID-19

Severe COVID-19 case was identified as a COVID-19 case (RT-PCR \[CLIA-certified central or local\] laboratory) for SARS-CoV-2, together with any of the following: respiratory rate ≥30 per minute, heart rate ≥125 beats per minute, oxygen saturation(SpO2) ≤93% on room air at sea level, or partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FIO2) \<300 millimeters of mercury (mmHg); or respiratory failure or acute respiratory distress syndrome (ARDS), defined as needing high-flow oxygen, noninvasive or mechanical ventilation, or extracorporeal membrane oxygenation) or evidence of shock (systolic blood pressure \<90 mm Hg, diastolic BP \<60 mm Hg, or requiring vasopressors); or significant acute renal, hepatic, or neurologic dysfunction; OR admission to an intensive care unit or death. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
14 days after second and third injection
Reported as:
Count of participants · Participants
Part A: Number of Healthy Participants With the Occurrence of Severe COVID-19
ParticipantsHealthy Participants
Part A: Number of Healthy Participants With the Occurrence of Severe COVID-190
SecondaryParts A and B: Number of SOT Participants Who Changed Immunosuppressant Therapy

A summary of serious adverse events (SAEs) and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
Throughout the study period (up to Day 450)
Reported as:
Count of participants · Participants
Parts A and B: Number of SOT Participants Who Changed Immunosuppressant Therapy
ParticipantsSOT Kidney ParticipantsSOT Liver ParticipantsSOT Total
Parts A and B: Number of SOT Participants Who Changed Immunosuppressant Therapy523789

Adverse events

Collected over All-cause mortality and serious adverse events were collected throughout the entire period of the study (from Day 1 up to the end of study [Day 450]). Unsolicited AEs were collected for 28 days after the vaccination.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SOT Kidney Participants4/137 (2.9%)28/137 (20.4%)49/137 (35.8%)
SOT Liver Participants0/77 (0%)17/77 (22.1%)38/77 (49.4%)
SOT Total4/214 (1.9%)45/214 (21%)87/214 (40.7%)
Healthy Participants0/20 (0%)1/20 (5%)13/20 (65%)
Most frequent serious events
Showing 10 of 90
Most frequent serious events
EventSOT Kidney ParticipantsSOT Liver ParticipantsSOT TotalHealthy Participants
Acute kidney injuryRenal and urinary disorders9/1372/7711/2140/20
Diverticulitis meckel'sCongenital, familial and genetic disorders0/1370/770/2141/20
Urinary tract infectionInfections and infestations4/1370/774/2140/20
Liver transplant rejectionImmune system disorders0/1372/772/2140/20
Transplant rejectionImmune system disorders0/1372/772/2140/20
HyperkalaemiaMetabolism and nutrition disorders1/1372/773/2140/20
SyncopeNervous system disorders0/1372/772/2140/20
NauseaGastrointestinal disorders0/1372/772/2140/20
VomitingGastrointestinal disorders1/1372/773/2140/20
FallInjury, poisoning and procedural complications1/1372/773/2140/20
Most frequent other events
Showing 10 of 50
Most frequent other events
EventSOT Kidney ParticipantsSOT Liver ParticipantsSOT TotalHealthy Participants
NasopharyngitisInfections and infestations2/1371/773/2143/20
Urinary tract infectionInfections and infestations14/1375/7719/2140/20
Ear infectionInfections and infestations0/1370/770/2142/20
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/1370/772/2142/20
Blood creatinine increasedInvestigations10/1377/7717/2140/20
Alanine aminotransferase increasedInvestigations2/1376/778/2140/20
Aspartate aminotransferase increasedInvestigations1/1375/776/2140/20
Abdominal painGastrointestinal disorders3/1374/777/2140/20
NauseaGastrointestinal disorders2/1374/776/2141/20
Blood urea increasedInvestigations2/1374/776/2140/20

Baseline characteristics

Safety set included all participants who received at least 1 dose of study drug in this study.

Age, Categorical
Age, Categorical(Participants)SOT Kidney ParticipantsSOT Liver ParticipantsHealthy ParticipantsTotal
<=18 years0000
Between 18 and 65 years1085818184
>=65 years2919250
Sex: Female, Male
Sex: Female, Male(Participants)SOT Kidney ParticipantsSOT Liver ParticipantsHealthy ParticipantsTotal
Female623810110
Male753910124
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SOT Kidney ParticipantsSOT Liver ParticipantsHealthy ParticipantsTotal
Hispanic or Latino155222
Not Hispanic or Latino1217118210
Unknown or Not Reported1102
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SOT Kidney ParticipantsSOT Liver ParticipantsHealthy ParticipantsTotal
American Indian or Alaska Native1012
Asian83213
Native Hawaiian or Other Pacific Islander0000
Black or African American2313339
White945511160
More than one race1203
Unknown or Not Reported104317
09

Study locations

15 sites
  • Aventiv Research Inc
    Mesa, Arizona 85206, United States
  • California Institute of Renal Research
    San Diego, California 92123, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06519, United States
  • Tampa General Medical Group
    Tampa, Florida 33606, United States
  • Piedmont Transplant Institute
    Atlanta, Georgia 30309, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • University of Massachusetts Medical School
    Worcester, Massachusetts 01655, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Northwell Health
    Manhasset, New York 11030, United States
  • Colombia University Medical Center
    New York, New York 10032, United States
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
  • Cleveland Clinic Hospital
    Cleveland, Ohio 44195, United States
  • Hospital of The University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in May 2023, 25 months.

Results were first posted in Jun 2024, 1 year after primary completion.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 25 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2021
First posted
Apr 26, 2021
StartActual
Apr 16, 2021
Primary completionActual
May 22, 2023
CompletionActual
May 22, 2023
Results first posted
Jun 18, 2024
Last update
Jun 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04860297
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Apr 26, 2021
Start date
Apr 16, 2021
Primary completion
May 22, 2023
Completion
May 22, 2023
Results posted
Jun 18, 2024
Last update
Jun 18, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 2019-nCoV Vaccine mRNA-1273

Start the discussion